APRE - Aprea's late-stage cancer trial fails to meet main-goal shares down 73% premarket

Aprea Therapeutics' (APRE) late-stage trial of its cancer combo treatment failed to meet the main goal of complete remission ((CR)) rate in patients with a form of myelodysplastic syndrome.The study aims to test the safety and efficacy of eprenetapopt with azacitidine ((AZA)) versus AZA alone in TP53 mutant myelodysplastic syndromes ((MDS)).The primary data from its Phase 3 clinical trial showed a higher CR rate in the experimental arm receiving eprenetapopt with AZA versus the control arm receiving AZA alone, but did not reach statistical significance.The CR rate in the eprenetapopt with AZA arm was 33.3% compared to 22.4% in the AZA alone arm.“We will continue to analyze data as it matures and follow patients who are still receiving study treatment. Our other clinical trials continue to progress and we remain committed to pursuing our clinical development programs,” Eyal Attar, Chief Medical Officer of Aprea said.APRE was down 73% premarket.

For further details see:

Aprea's late-stage cancer trial fails to meet main-goal, shares down 73% premarket